{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:26Z","timestamp":1785545006014,"version":"3.56.0"},"reference-count":29,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Primary biliary cholangitis (PBC) management remains limited by reliance on static biochemical markers, fragmented assessment of symptom burden, and inadequate noninvasive risk stratification for clinically significant portal hypertension (CSPH). Existing tools fail to integrate longitudinal laboratory trends, elastography, and patient-reported outcomes, and translation of risk assessment into guideline-concordant clinical action remains inconsistent.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to develop, validate, and pilot an explainable artificial intelligence (AI) framework\u2014AIm-PBC\u2014for continuous disease monitoring, early prediction of CSPH complications, and delivery of guideline-based clinical decision support in patients with PBC.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We will conduct a multiphase study combining retrospective cohort analysis, prospective observational data collection, and implementation evaluation. At least 600 adults with confirmed PBC will be enrolled across academic hepatology centers. The AI framework will integrate longitudinal biochemical markers, noninvasive elastography metrics, and high-frequency patient-reported outcomes to generate an interpretable disease activity index and predict CSPH-related complications using gradient-boosted models with Shapley additive explanations. Outputs will be deployed via a SMART-on-FHIR (Substitutable Medical Applications, Reusable Technologies on Fast Healthcare Interoperability Resources)\u2013enabled electronic health record clinical decision support tool. Implementation will be evaluated using a randomized crossover simulation followed by a pragmatic pilot assessing usability, cognitive load, clinician adherence, and feasibility.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The primary outcomes include calibration and responsiveness of the disease activity index; discriminatory performance of the CSPH prediction model compared with established criteria; and effectiveness of the decision support tool measured via improvements in guideline-concordant care, usability scores, and clinician cognitive workload. Secondary outcomes include fairness metrics and workflow efficiency.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This protocol outlines a scalable, explainable AI framework designed to bridge gaps between disease monitoring, risk prediction, and clinical action in PBC. If successful, AIm-PBC may enhance early complication detection, improve symptom management, and support equitable, evidence-based care delivery in routine hepatology practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/89279","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:05:08Z","timestamp":1779743108000},"page":"e89279-e89279","source":"Crossref","is-referenced-by-count":0,"title":["An Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis: Protocol for a Multiphase Development and Validation Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0714-4368","authenticated-orcid":false,"given":"Basile","family":"Njei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6791-1018","authenticated-orcid":false,"given":"Ulrick","family":"Sidney Kanmounye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"8","key":"R1","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","journal-title":"Hepatology"},{"issue":"6","key":"R3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70118","article-title":"Quality measures to enhance the management and treatment of primary biliary cholangitis: a Delphi consensus study","volume":"45","author":"Alvaro","journal-title":"Liver Int"},{"issue":"1","key":"R4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","journal-title":"J Hepatol"},{"issue":"2","key":"R5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5152\/tjg.2023.22239","article-title":"Management of primary biliary cholangitis: current treatment and future perspectives","volume":"34","author":"Barba Bernal","journal-title":"Turk J Gastroenterol"},{"issue":"5","key":"R6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah","journal-title":"Liver Int"},{"issue":"6","key":"R7","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment","volume":"7","author":"Trivella","journal-title":"Hepatol Commun"},{"issue":"17","key":"R8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175713","article-title":"Risk stratification in primary biliary cholangitis","volume":"12","author":"Martini","journal-title":"J Clin Med"},{"issue":"1","key":"R9","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100031","article-title":"Spleen stiffness measurement as a non-invasive assessment in patients with portal hypertension","volume":"2","author":"Xu","journal-title":"eGastroenterology"},{"issue":"10","key":"R10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/hep4.1567","article-title":"A systematic review of patient-reported outcomes in primary biliary cholangitis and primary sclerosing cholangitis","volume":"4","author":"Kim","journal-title":"Hepatol Commun"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03798-x","article-title":"Psychometric validation of the Worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis","volume":"20","author":"Gelhorn","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"R12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/liv.15141","article-title":"Machine learning in primary biliary cholangitis: a novel approach for risk stratification","volume":"42","author":"Gerussi","journal-title":"Liver Int"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59183-4","article-title":"An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis","volume":"14","author":"Njei","journal-title":"Sci Rep"},{"issue":"1","key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(25)01246-6","article-title":"534: FibroX: an explainable AI model for accurate prediction of advanced liver fibrosis and cardiovascular mortality in MASLD","volume":"169","author":"Njei","journal-title":"Gastroenterology"},{"issue":"11","key":"R15","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.cgh.2020.06.062","article-title":"Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy","volume":"19","author":"Montano-Loza","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16","unstructured":"Tsoris A Marlar CA . Use of the Child Pugh score in liver disease. In: StatPearls. StatPearls Publishing; 2019."},{"issue":"6","key":"R17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1080\/00952990.2018.1456545","article-title":"A review of the Alcohol Use Disorders Identification Test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: past issues and future directions","volume":"44","author":"Higgins-Biddle","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"R18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","journal-title":"Hepatology"},{"issue":"3","key":"R19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.14218\/JCTH.2021.00008","article-title":"Characteristics and inpatient outcomes of primary biliary cholangitis and autoimmune hepatitis overlap syndrome","volume":"9","author":"Jiang","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"R20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.18134","article-title":"The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis","volume":"60","author":"Hern\u00e1ndez-P\u00e9rez","journal-title":"Aliment Pharmacol Ther"},{"key":"R21","volume":"74","author":"Zachariah","journal-title":"Gut"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","journal-title":"Hepatology"},{"issue":"15","key":"R23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154497","article-title":"The external validation of GLOBE and UK-PBC risk scores for predicting ursodeoxycholic acid treatment response in a large U.S. cohort of primary biliary cholangitis patients","volume":"13","author":"Marenco-Flores","journal-title":"J Clin Med"},{"issue":"4","key":"R24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","journal-title":"J Hepatol"},{"issue":"1","key":"R25","doi-asserted-by":"publisher","first-page":"101577","DOI":"10.1016\/j.aohep.2024.101577","article-title":"Clinically significant portal hypertension in patients with primary biliary cholangitis: clinicopathological features and prognostic value","volume":"30","author":"Zhang","journal-title":"Ann Hepatol"},{"issue":"5","key":"R26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.5009\/gnl230468","article-title":"Precirrhotic primary biliary cholangitis with portal hypertension: bile duct injury correlate","volume":"18","author":"Hu","journal-title":"Gut Liver"},{"issue":"7","key":"R27","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes","volume":"38","author":"Riley","journal-title":"Stat Med"},{"issue":"10491","key":"R28","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(25)00770-6","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomised trials","volume":"405","author":"Chan","journal-title":"Lancet"},{"key":"R29","unstructured":"OpenAI. ChatGPT. URL: https:\/\/chatgpt.com\/ [Accessed 12-06-2026]"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e89279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:24:41Z","timestamp":1785536681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e89279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2196\/89279","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"v15i8e89279"}}